Transcatheter closure of perimembranous XXXX with amplatzer membranous occluder.

@entity1 @entity713 @entity2142 @entity5512 @entity1757 @entity5036 @entity337 @entity8526 @entity616 @entity884
BACKGROUND: Use of trancatheter device closure for membranous @entity1757 is still in evolving phase. We report the early and mid-term results of our experience with the new asymmetric Amplatzer membranous @entity1757 occluder. METHODS AND RESULTS: We attempted, transcatheter closure of perimembranous @entity1757 using asymmetric Amplatzer occluder in 26 @entity1 . The @entity1 were selected on the basis of transthoracic and transesophageal echocardiographic assessment of the @entity1757 . The procedure was successful in 21 (81%) @entity1 . The age ranged from 3 to 23 years, weight from 10 to 59 kg and defect size ranged from 3 to 9 mm (mean: 5 +/- 1.8 mm). One @entity1 had situs inversus with @entity5512 : 11 had aneurysmal tissue partly occluding the defect and the device was deployed either across (n=6) or within the aneurysmal sac (n=5). Three @entity1 developed high degree @entity713 on attempts to cross the defect with the sheath and the procedure was discontinued. In two @entity1 it was not possible to place the sheath in left ventricle despite repeated attempts. There was a residual flow in 4 (19%) @entity1 at 24 hours. Two @entity1 developed @entity5036 and none had complete @entity616 . At follow-up (1-9 months, n=20), residual flow was seen in two @entity1 . None developed late @entity8526 , @entity337 , @entity884 or @entity2142 . CONCLUSIONS: Transcatheter closure of perimembranous @entity1757 can be performed safely and effectively with the new asymmetric Amplatzer occluder device in selected @entity1 with good short- and midterm results. These devices can be deployed safely in and across and the aneurysmal sacs. In selected cases, this procedure is a satisfactory alternative to surgery.
